Category: biotech

.Veteran equity capital company venBio has actually lifted another half a billion dollars to invest in biotechs working with diseases along with unmet need. The

.After introducing a phase 3 launch based upon positive midstage results, iTeos and also GSK are eventually sharing the highlights from the period 2 TIGIT

.Zevra Therapeutics’ rare condition medicine appears to become on the road to authorization this fall after gaining the backing of an FDA advisory committee, although

.Otsuka Drug’s renal condition medicine has attacked the main endpoint of a period 3 trial by displaying in an interim study the reduction of individuals’

.Bicara Therapeutics as well as Zenas Biopharma have actually delivered fresh catalyst to the IPO market along with filings that explain what recently public biotechs

.CEO David Ricks can view the companies putting together outdoors tents at basecamp responsible for Eli Lilly in a try to obtain a foothold of

.After rearing $213 thousand in 2023– among the year’s largest private biotech rounds– Tome Biosciences is making cuts.” Regardless of our crystal clear clinical progress,

.As biotechs seek to switch a fresh webpage in August, at the very least three firms have actually dropped team in attempts to create on.

.OncoC4 is taking AcroImmune– and its own internal medical manufacturing capabilities– under its own fly an all-stock merger.Both cancer biotechs were co-founded by OncoC4 chief

.Zephyrm Bioscience is gusting towards the Hong Kong stock exchange, filing (PDF) for an IPO to money phase 3 tests of its tissue treatment in